Comment on CMS-2026-1256-0002

Summary: AtriCure, a medical device company, opposes the proposed elimination of alternative approval pathways for New Technology Add-On Payments (NTAP) and transitional pass-through payments for breakthrough devices. They argue that these pathways are essential for timely patient access to innovative technologies and request that CMS instead consider refinements that maintain these pathways while addressing cost and "newness" concerns.